3.01

24.38% 0.59

After Hours: 3.15 0.14 +4.65%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $3.01, with a volume of 4.54M. It is up +24.38% in the last 24 hours and down -23.02% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$2.42

Open:

$2.6

24h Volume:

4.54M

Relative Volume:

3.42

Market Cap:

$118.28M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.7399

EPS:

-1.73

Net Cash Flow:

$-54.24M

1W Performance:

+33.19%

1M Performance:

-23.02%

6M Performance:

-72.44%

1Y Performance:

-83.90%

1-Day Range:

$2.48

$3.05

1-Week Range:

$1.76

$3.05

52-Week Range:

$1.76

$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

154

Twitter

@CabalettaBio

Next Earnings Date

2024-11-07

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	3.01	118.28M	0	-67.68M	-54.24M	-1.73
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

Nov 26, 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times

Nov 26, 2024

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% To 1,183% In 2025 - Barchart

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 - TradingView

Nov 25, 2024

Nov 24, 2024

Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN

Nov 24, 2024

Nov 22, 2024

Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN

Nov 22, 2024

Nov 21, 2024

Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com

Nov 21, 2024

Nov 20, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN

Nov 20, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN

Nov 20, 2024

Nov 19, 2024

Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com

Nov 19, 2024

Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia

Nov 19, 2024

Nov 18, 2024

Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times

Nov 18, 2024

Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat

Nov 16, 2024

Nov 15, 2024

Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK

Nov 15, 2024

Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 15, 2024